Tarsus CEO Azamian exercises 66,274 RSUs

Tarsus Pharmaceuticals, Inc. reported that President/CEO and Board Chair Bobak R. Azamian exercised and settled restricted stock units into common shares.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. reported that President/CEO and Board Chair Bobak R. Azamian exercised and settled restricted stock units into common shares. On March 15, 2026, he converted RSUs covering 66,274 shares of common stock at a conversion price of $0.00 per share.

After these settlements, his directly held common stock position reported in this filing is 68,024 shares. He also has an indirect holding of 857,991 common shares through the Bobak Azamian Living Trust established April 16, 2018, where he has voting and dispositive power over the shares.

Insider Trade Summary

66,274 shares exercised/converted

Exercise 6 txns

Insider Azamian Bobak R.

Role President/CEO and Board Chair

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	11,300	$0.00	$0.00
Exercise	Restricted Stock Units	16,975	$0.00	$0.00
Exercise	Restricted Stock Units	23,121	$0.00	$0.00
Exercise	Restricted Stock Units	14,878	$0.00	$0.00
Exercise	Common Stock	66,274	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 107,852 contracts (Direct); Common Stock — 68,024 shares (Direct); Common Stock — 857,991 shares (Indirect, By the Bobak Azamian Living Trust established April 16, 2018)

Footnotes (7)

1. F1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
2. F2. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
3. F3. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.
4. F4. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.
5. F5. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
6. F6. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
7. F7. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tarsus (TARS) CEO Bobak Azamian report in this Form 4?

Bobak Azamian reported the settlement of restricted stock units into common shares. On March 15, 2026, RSUs covering 66,274 shares were converted at $0.00, increasing his directly held Tarsus common stock to 68,024 shares.

How many Tarsus (TARS) shares did the CEO acquire through RSU settlement?

The CEO acquired 66,274 Tarsus common shares through settlement of vested restricted stock units. Each RSU represented a right to receive one share, and the conversion occurred on March 15, 2026 at a stated price of $0.00 per share.

What are Bobak Azamian’s direct and indirect Tarsus (TARS) share holdings?

Following the reported transactions, Bobak Azamian directly holds 68,024 Tarsus common shares. He also indirectly holds 857,991 common shares through the Bobak Azamian Living Trust, where he has voting and dispositive power over the trust’s holdings.

Were the Tarsus (TARS) CEO’s restricted stock units tied to a stock plan?

Yes. The restricted stock units were granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan across multiple grant dates. Each RSU grant vests in 25% annual installments on March 15 of specified years, subject to his continuous service.

Did the Tarsus (TARS) Form 4 show any open-market stock sales by the CEO?

No open-market stock sales were reported in this Form 4. The transactions involved exercises and settlements of restricted stock units into common shares, with no sale transactions or tax-withholding dispositions disclosed in the provided data.

What role does the Bobak Azamian Living Trust play in Tarsus (TARS) holdings?

The Bobak Azamian Living Trust holds 857,991 Tarsus common shares indirectly for the CEO. He serves as trustee and has voting and dispositive power over these shares, according to the disclosure footnote describing the trust arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Azamian Bobak R.

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President/CEO and Board Chair

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		66,274	A	(1)	68,024	D
Common Stock								857,991	I	By the Bobak Azamian Living Trust established April 16, 2018(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	03/15/2026		M			11,300	(4)	(4)	Common Stock	11,300	$0	0	D
Restricted Stock Units	(3)	03/15/2026		M			16,975	(5)	(5)	Common Stock	16,975	$0	16,975	D
Restricted Stock Units	(3)	03/15/2026		M			23,121	(6)	(6)	Common Stock	23,121	$0	46,243	D
Restricted Stock Units	(3)	03/15/2026		M			14,878	(7)	(7)	Common Stock	14,878	$0	44,634	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

2. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

3. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

4. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

5. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

6. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

7. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.